Literature DB >> 15789425

Temporally controlled targeted somatic mutagenesis in skeletal muscles of the mouse.

Michael Schuler1, Faisal Ali, Elisabeth Metzger, Pierre Chambon, Daniel Metzger.   

Abstract

To generate temporally controlled targeted somatic mutations selectively and efficiently in skeletal muscles, we established a transgenic HSA-Cre-ER(T2) mouse line in which the expression of the tamoxifen-dependent Cre-ER(T2) recombinase is under the control of a large genomic DNA segment of the human skeletal muscle alpha-actin gene, contained in a P1-derived artificial chromosome. In this transgenic line Cre-ER(T2) is selectively expressed in skeletal muscles, and Cre-ER(T2)-mediated alteration of LoxP flanked (floxed) target genes is skeletal muscle-specific and strictly tamoxifen-dependent. HSA-Cre-ER(T2) mice should be of great value to analyze gene function in skeletal muscles, and to establish animal models of human skeletal muscle disorders. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15789425     DOI: 10.1002/gene.20107

Source DB:  PubMed          Journal:  Genesis        ISSN: 1526-954X            Impact factor:   2.487


  46 in total

1.  Skeletal Muscle-Specific Activation of Gq Signaling Maintains Glucose Homeostasis.

Authors:  Derek B J Bone; Jaroslawna Meister; Jonas R Knudsen; Diptadip Dattaroy; Amanda Cohen; Regina Lee; Huiyan Lu; Daniel Metzger; Thomas E Jensen; Jürgen Wess
Journal:  Diabetes       Date:  2019-04-01       Impact factor: 9.461

2.  A tetracycline-inducible and skeletal muscle-specific Cre recombinase transgenic mouse.

Authors:  Pengcheng Rao; D Ashley Monks
Journal:  Dev Neurobiol       Date:  2009-05       Impact factor: 3.964

3.  Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.

Authors:  Belinda S Cowling; Thierry Chevremont; Ivana Prokic; Christine Kretz; Arnaud Ferry; Catherine Coirault; Olga Koutsopoulos; Vincent Laugel; Norma B Romero; Jocelyn Laporte
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

4.  Loss of mitochondrial calcium uniporter rewires skeletal muscle metabolism and substrate preference.

Authors:  Gaia Gherardi; Leonardo Nogara; Stefano Ciciliot; Gian Paolo Fadini; Bert Blaauw; Paola Braghetta; Paolo Bonaldo; Diego De Stefani; Rosario Rizzuto; Cristina Mammucari
Journal:  Cell Death Differ       Date:  2018-09-19       Impact factor: 15.828

5.  RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.

Authors:  Johanna E Lee; C Frank Bennett; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

6.  A series of Cre-ER(T2) drivers for manipulation of the skeletal muscle lineage.

Authors:  Sheryl Southard; SiewHui Low; Lydia Li; Michelle Rozo; Tyler Harvey; Chen-Ming Fan; Christoph Lepper
Journal:  Genesis       Date:  2014-06-03       Impact factor: 2.487

7.  Skeletal myofiber VEGF is essential for the exercise training response in adult mice.

Authors:  Hamid Delavar; Leonardo Nogueira; Peter D Wagner; Michael C Hogan; Daniel Metzger; Ellen C Breen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-12       Impact factor: 3.619

8.  Gli3 regulation of myogenesis is necessary for ischemia-induced angiogenesis.

Authors:  Marie-Ange Renault; Soizic Vandierdonck; Candice Chapouly; Yang Yu; Gangjian Qin; Alexandre Metras; Thierry Couffinhal; Douglas W Losordo; Qinyu Yao; Annabel Reynaud; Béatrice Jaspard-Vinassa; Isabelle Belloc; Claude Desgranges; Alain-Pierre Gadeau
Journal:  Circ Res       Date:  2013-09-17       Impact factor: 17.367

9.  Temporal and tissue-specific disruption of LINC complexes in vivo.

Authors:  David Razafsky; Didier Hodzic
Journal:  Genesis       Date:  2014-03-10       Impact factor: 2.487

10.  Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy.

Authors:  James P Orengo; Pierre Chambon; Daniel Metzger; Dennis R Mosier; G Jackson Snipes; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.